Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 12 January 2026 - 14 January 2026

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

New York, Jan 14, 2026, 12:38 PM ET — Regular session Shares of Erasca Inc jumped roughly 10% Wednesday, pushing higher after a string of price-target upgrades fueled by early trial results. The clinical-stage cancer drugmaker’s stock hit $8.29, up 10.5%. The significance lies in Erasca having no approved products. In early-stage biotech, just a few signs of tumor shrinkage…
14 January 2026
·····
KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

New York, Jan 13, 2026, 16:15 EST — After-hours Kiniksa Pharmaceuticals International, plc saw its shares drop 6.1% to $38.61 on Tuesday, following the release of updated revenue forecasts for its key drug ARCALYST. The stock briefly dipped to an intraday low of $38.27. Yahoo Finance The move matters because ARCALYST is carrying the load: it serves as the company’s…
13 January 2026
·····
GeneDx stock drops again: WGS slides on 2026 outlook as JPM talk nears

GeneDx stock drops again: WGS slides on 2026 outlook as JPM talk nears

New York, Jan 13, 2026, 14:49 EST — Regular session Shares of GeneDx Holdings Corp dropped roughly 8.7% to $108.90 Tuesday afternoon, continuing their slide after the genetic testing firm revealed its 2026 revenue forecast the previous day. (Yahoo) The drop is significant since GeneDx is now viewed as a high-expectations play: investors are swift to punish results that merely…
13 January 2026
····
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

NEW YORK, Jan 13, 2026, 12:18 EST — Regular session Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech. (Reuters) This shift is significant as major drugmakers ramp up their push for obesity pills.…
13 January 2026
······
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

New York, January 13, 2026, 11:31 EST — Regular session Moderna shares were up $3.97, or 11.7%, at $37.81 by late morning in New York, lifting the vaccine maker to one of the stronger movers in biotech trading. The bounce comes as investors try to pin down what “post-pandemic Moderna” looks like — smaller, more volatile, and still dependent on…
13 January 2026
····
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

New York, Jan 13, 2026, 10:45 (EST) — Regular session ImmunityBio, Inc. shares rose about 6% on Tuesday after the company released new lung cancer trial results tied to its immune-boosting drug ANKTIVA. The stock was up 6.4% at $2.76, after touching $2.85 earlier in the session. The move matters because ImmunityBio is trying to widen the case for ANKTIVA…
13 January 2026
·····
Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

New York, Jan 12, 2026, 18:31 EST — After-hours Thermo Fisher Scientific Inc shares slipped roughly 0.5% in Monday’s after-hours session, following the life-sciences tools company’s announcement of a fresh partnership with Nvidia and a shake-up in its leadership team. The timing is crucial. Investors have rapidly backed any sign of renewed growth for lab suppliers following a rocky period…
13 January 2026
······
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

NEW YORK, Jan 12, 2026, 15:29 (EST) — Trading in the regular session. Caris Life Sciences shares dropped roughly 8.5% to $26.08 in afternoon trading, after fluctuating between $25.35 and $29.77 earlier today. The update comes amid J.P. Morgan Healthcare Conference week, a time when healthcare firms typically try to recalibrate expectations ahead of earnings season. Investors are focused on…
12 January 2026
····
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

New York, Jan 12, 2026, 2:46 PM EST — Regular session Shares of GeneDx Holdings Corp dropped roughly 14% Monday following the release of its 2026 outlook and preliminary results for 2025. The stock slipped $19.64 to trade at $115.75 in afternoon sessions. The scale of the shift highlights how fast investors are revaluing healthcare stocks releasing early results this…
12 January 2026
···
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

New York, Jan 12, 2026, 14:44 ET — Regular session underway Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded. (SEC) This is crucial now…
12 January 2026
·····
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

New York, Jan 12, 2026, 2:38 PM EST — Regular session Shares of Johnson & Johnson climbed roughly 2.3% to $209.03 on Monday, pushing the stock near the high end of its trading range after new oncology data came out over the weekend. This move is crucial as major drugmakers face mounting pressure to demonstrate lasting growth ahead of earnings…
12 January 2026
·····
Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

New York, Jan 12, 2026, 13:43 EST — Regular session Shares of Twist Bioscience Corp jumped roughly 8% Monday following a preliminary first-quarter revenue report that beat expectations. The synthetic DNA company’s stock climbed 7.8% to $38.07 in afternoon trading, trading between $34.51 and $39.80 earlier in the session. The timing is key. Firms are releasing early results just as…
12 January 2026
···
1 2 3 4 5 6 … 24

Stock Market Today

  • Parex Resources Shows Continued Rebound in Oil Sector
    February 2, 2026, 8:48 AM EST. Parex Resources continues its rebound amid volatility in the oil and gas industry, known for its cyclical boom-bust cycles. The company's recovery is highlighted by focused investor interest from experienced analysts who emphasize patience and thorough research. With oil prices and midstream segments fluctuating, Parex offers potential value to long-term investors seeking exposure to under-followed energy stocks. This analysis appears with a disclosure of a beneficial long position in Parex shares, underscoring active market engagement but does not constitute investment advice. Investors should conduct their own due diligence when considering Parex Resources for their portfolios.
Go toTop